Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Women's HealthIssue 669

Two Glucose Uptake Mechanisms Affected by Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) poses a double impact in glucose control in women with the highest level of insulin resistance....

Advertisement

A recent study, compared 28 healthy women with 28 with PCOS showing that women with PCOS had a decrease in both insulin and non-insulin glucose controlling mechanisms. PCOS participants with the most insulin resistance at the start of the trial had results that showed a decline in their ability to compensate with non-insulin glucose controlling mechanisms.

Dr. Ricardo Azziz, reproductive endocrinologist and PCOS expert at Georgia Regents University, states, "Women with PCOS who have the highest levels of insulin resistance, the greatest difficulty controlling their sugar and the highest risk for diabetes, appear to have a double defect in how glucose is controlled, which affects both the mechanisms that use insulin and those that do not." The study measured visceral and subcutaneous fat distribution, which predicted the degree of insulin and non-insulin glucose control, respectively.

"If the fat is not as sensitive to insulin, that obviously means blood sugar levels, and probably fat and cholesterol levels as well, increase and the pancreas responds by producing more insulin," Azziz said. "Fat abnormalities can have a tremendous impact on how we feel and how we function."

In the future, the researchers want to construct a study that includes understanding the molecular mechanisms involved in how PCOS affects glucose usage.

Journal of Clinical Endocrinology & Metabolism, 2013; DOI: 10.1210/jc.2012-2937 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 21 March, 2013 and appeared in  Women's HealthIssue 669

Past five issues: Diabetes Clinical Mastery Series Issue 208 | Issue 748 | GLP-1 Special Editions September 2014 | Diabetes Clinical Mastery Series Issue 207 | Issue 747 |

2014 Most Popular Articles:

Abbott Announces Approval of Its New Unique Continuous Glucose Monitor
Posted September 05, 2014
Low Carb Beats Low Fat
Posted September 05, 2014
FDA Approves Bupropion/Naltrexone (Contrave) for Obesity by Orexigen Therapeutics
Posted September 12, 2014
Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus
Posted September 05, 2014
An Exclusive Interview with Al Mann, Founder and CEO, Mannkind Corp.
Posted September 15, 2014
Empagliflozin (Jardiance) SGLT-2 Inhibitor Now Available in Pharmacies
Posted August 29, 2014
Sleeve Gastrectomy Now a Common Choice for Bariatric Surgery
Posted September 12, 2014
Type 2 Diabetes Diagnosis Needs to Be Changed: Prediabetes=Diabetes
Posted September 12, 2014
Predicting Which Diabetics Will Develop Major Complications
Posted September 05, 2014
High-salt Diet and High HBA1c May Increase Cardiovascular Disease
Posted September 19, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Now that once-weekly dulaglutide has been approved, will you be prescribing it?
CME/CE of the Week
Silvia Inzucchi, MD

Category: General Diabetes
Credits: .75
Search Articles On Diabetes In Control